Skip to content

Evaluation of methylphenidate on level of conciseness and hospital length of stay in patients with severe and moderate acute traumatic brain injury

Evaluation of methylphenidate on level of conciseness and hospital length of stay in patients with severe and moderate acute traumatic brain injury

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140915019185N3
Enrollment
62
Registered
2020-09-22
Start date
2020-09-22
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate and severe brain trauma. Diffuse traumatic brain injury

Interventions

Intervention 1: Patients with moderate to severe brain injury and level of consciousness (GCS) between 5 and 12 who do not have surgery for hemorrhagic lesion on CT scan.they will receive methylphenyd

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 75 Years

Inclusion criteria

Inclusion criteria: Moderate to severe brain damage and level of consciousness (GCS) between 5 and 12 that do not require surgery.

Exclusion criteria

Exclusion criteria: Children under 15 Adults over 75 years Very severe trauma accompanied by especially chest and abdomen Death in the first 48 hours History of untreated heart disease or uncontrolled hypertension Patients with unstable vital signs (fever above 39 degrees - uncontrolled infectious disease - hypotension - acute renal failure and high creatinine ..) Emergency craniotomy

Design outcomes

Primary

MeasureTime frame
Level of conciseness. Timepoint: the days 2,7 and discharge time. Method of measurement: GCS.

Secondary

MeasureTime frame
Delirium. Timepoint: Day 2 and day 7 and at discharge. Method of measurement: The incidence of delirium is first assessed by the RASS scale for level of consciousness and then by the CAM-ICU scale for delirium.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKaveh Haddadi

Mazandaran University of Medical Sciences

k.haddadi@mazums.ac.ir+98 11 3336 1630

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026